S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Laser breakthrough could send stock soaring 2,467% (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Laser breakthrough could send stock soaring 2,467% (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Laser breakthrough could send stock soaring 2,467% (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Laser breakthrough could send stock soaring 2,467% (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Laser breakthrough could send stock soaring 2,467% (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
NASDAQ:SNGX

Soligenix (SNGX) Stock Forecast, Price & News

$0.53
+0.03 (+5.58%)
(As of 09/22/2023 08:52 PM ET)
Compare
Today's Range
$0.50
▼
$0.53
50-Day Range
$0.44
▼
$0.69
52-Week Range
$0.42
▼
$10.93
Volume
45,300 shs
Average Volume
372,408 shs
Market Capitalization
$4.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Soligenix MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
466.0% Upside
$3.00 Price Target
Short Interest
Healthy
0.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.56) to ($1.74) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

See Top Rated MarketRank™ Stocks Here

SNGX stock logo

About Soligenix (NASDAQ:SNGX) Stock

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

SNGX Price History

SNGX Stock News Headlines

September 22, 2023 | prnewswire.com
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
August 24, 2023 | finance.yahoo.com
SNGX: HyBryte™ Expanded Treatment Trial Underway
September 25, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
August 21, 2023 | finanznachrichten.de
Soligenix, Inc.: Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
August 21, 2023 | msn.com
Soligenix GAAP EPS of -$0.22 beats by $0.16, revenue of $0.2M in-line
August 21, 2023 | finance.yahoo.com
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
August 2, 2023 | finance.yahoo.com
SNGX - Soligenix, Inc.
July 19, 2023 | finance.yahoo.com
SNGX: Expanding SGX302 Phase 2a Study in Psoriasis…
September 25, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
June 29, 2023 | finance.yahoo.com
Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily
June 2, 2023 | finanznachrichten.de
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report
June 2, 2023 | finance.yahoo.com
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
May 30, 2023 | finance.yahoo.com
SNGX: Positive Results for Compatibility Study of HyBryte in CTCL
May 16, 2023 | finanznachrichten.de
Soligenix, Inc.: Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
May 16, 2023 | finance.yahoo.com
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
May 15, 2023 | finance.yahoo.com
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results
May 11, 2023 | finance.yahoo.com
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
May 9, 2023 | finance.yahoo.com
Soligenix Announces Closing of $8.5 Million Public Offering
May 5, 2023 | finance.yahoo.com
Soligenix Announces Pricing of $8.5 Million Public Offering
May 4, 2023 | finance.yahoo.com
Why Are Soligenix Shares Trading Higher Today
May 3, 2023 | finance.yahoo.com
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors
May 1, 2023 | finance.yahoo.com
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
April 24, 2023 | finance.yahoo.com
SNGX: Planning for Second Phase 3 Study for HyBryte™ in CTCL…
April 24, 2023 | finance.yahoo.com
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
April 14, 2023 | msn.com
Soligenix Shares Tumble as FDA Demands More Data
April 14, 2023 | msn.com
Soligenix stock sinks as FDA seeks additional positive results for cancer drug
April 14, 2023 | finance.yahoo.com
Soligenix Provides Regulatory Update on HyBryte™
See More Headlines
Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Company Calendar

Last Earnings
8/21/2023
Today
9/24/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNGX
CUSIP
N/A
CIK
812796
Web
www.soligenix.com
Phone
(609) 538-8200
Fax
609-452-6467
Employees
13
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+466.0%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,800,000.00
Net Margins
-943.00%
Pretax Margin
-1,056.62%
Return on Equity
-3,826.28%
Return on Assets
-65.21%

Debt

Debt-to-Equity Ratio
0.36
Current Ratio
2.34
Quick Ratio
2.34

Sales & Book Value

Annual Sales
$950,000.00
Price / Sales
4.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.85) per share
Price / Book
-0.62

Miscellaneous

Outstanding Shares
8,120,000
Free Float
8,006,000
Market Cap
$4.30 million
Optionable
Not Optionable
Beta
1.67

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Christopher J. Schaber Ph.D.Dr. Christopher J. Schaber Ph.D. (Age 57)
    Chairman of Directors, CEO & Pres
    Comp: $638.13k
  • Mr. Jonathan L. Guarino CPAMr. Jonathan L. Guarino CPA (Age 50)
    CGMA, Sr. VP, CFO & Corp. Sec.
    Comp: $304.31k
  • Dr. Oreola Donini Ph.D. (Age 51)
    Sr. VP & Chief Scientific Officer
    Comp: $336.98k
  • Dr. Richard C. Straube M.D. (Age 71)
    MSc., Sr. VP & Chief Medical Officer
    Comp: $215.07k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SNGX Stock - Frequently Asked Questions

What is Soligenix's stock price forecast for 2023?

0 Wall Street research analysts have issued twelve-month price objectives for Soligenix's stock. Their SNGX share price forecasts range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 466.0% from the stock's current price.
View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts.

How have SNGX shares performed in 2023?

Soligenix's stock was trading at $0.4520 at the beginning of 2023. Since then, SNGX stock has increased by 17.3% and is now trading at $0.53.
View the best growth stocks for 2023 here.

Are investors shorting Soligenix?

Soligenix saw a decrease in short interest in August. As of August 31st, there was short interest totaling 24,900 shares, a decrease of 90.3% from the August 15th total of 255,600 shares. Based on an average daily trading volume, of 150,200 shares, the short-interest ratio is currently 0.2 days. Currently, 0.3% of the company's stock are short sold.
View Soligenix's Short Interest.

When is Soligenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SNGX earnings forecast.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings results on Monday, August, 21st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.32. The biopharmaceutical company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative net margin of 943.00% and a negative trailing twelve-month return on equity of 3,826.28%.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Anson Funds Management LP (6.33%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube.
View institutional ownership trends.

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.53.

How much money does Soligenix make?

Soligenix (NASDAQ:SNGX) has a market capitalization of $4.30 million and generates $950,000.00 in revenue each year.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467.

This page (NASDAQ:SNGX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -